Format

Send to

Choose Destination
Cells. 2019 May 17;8(5). pii: E472. doi: 10.3390/cells8050472.

Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy.

Author information

1
Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Member of the German Center for Lung Research (DZL), 80337 Munich, Germany. stefan.stoiber@campus.lmu.de.
2
Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Member of the German Center for Lung Research (DZL), 80337 Munich, Germany. bcadilha@gmail.com.
3
Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Member of the German Center for Lung Research (DZL), 80337 Munich, Germany. reda.benmebarek@gmail.com.
4
Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Member of the German Center for Lung Research (DZL), 80337 Munich, Germany. steffi-lesch@t-online.de.
5
Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Member of the German Center for Lung Research (DZL), 80337 Munich, Germany. Stefan.Endres@med.uni-muenchen.de.
6
German Center for Translational Cancer Research (DKTK), 80337 Munich, Germany. Stefan.Endres@med.uni-muenchen.de.
7
Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Member of the German Center for Lung Research (DZL), 80337 Munich, Germany. Sebastian.kobold@med.uni-muenchen.de.
8
German Center for Translational Cancer Research (DKTK), 80337 Munich, Germany. Sebastian.kobold@med.uni-muenchen.de.

Abstract

Cancer therapy has entered a new era, transitioning from unspecific chemotherapeutic agents to increasingly specific immune-based therapeutic strategies. Among these, chimeric antigen receptor (CAR) T cells have shown unparalleled therapeutic potential in treating refractory hematological malignancies. In contrast, solid tumors pose a much greater challenge to CAR T cell therapy, which has yet to be overcome. As this novel therapeutic modality matures, increasing effort is being invested to determine the optimal structure and properties of CARs to facilitate the transition from empirical testing to the rational design of CAR T cells. In this review, we highlight how individual CAR domains contribute to the success and failure of this promising treatment modality and provide an insight into the most notable advances in the field of CAR T cell engineering.

KEYWORDS:

CAR T cell; adoptive cell therapy; chimeric antigen receptor; immunotherapy

PMID:
31108883
DOI:
10.3390/cells8050472
Free full text

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI)
Loading ...
Support Center